Navigation Links
Malaria-curing Herb Must Be Carefully Farmed - WHO

The effectiveness of an anti-malarial herbal drug could be damaged by overplanting of the Chinese shrub from which it is derived//, the World Health Organization (WHO) said on Monday.

The artemisia annua (sweet wormwood) shrub must be more carefully farmed to meet a growing global demand and to keep fakes off the market, the United Nations agency said.

Chinese herbalists have used leaves from the shrub to treat malaria for centuries. It is now widely regarded as the best drug to treat the disease.

Not all shrubs yield enough for the malaria-fighting compound artemisinin to be effective against the mosquito-borne disease that kills a person every 30 seconds.

WHO urged governments to work closely with farmers and drug manufacturers to accurately estimate the demand for artemisinin while avoiding over-production that could hurt crop yields.

Workers also need more technical skills to properly extract artemisinin from dried leaves, it said.

"Not all artemisinin meets the required standards to produce quality medicines," the WHO said in guidelines calling for more stringent monitoring of the plant's cultivation and collection.

"The availability of these treatments still falls short of what is needed."

Resistance to conventional anti-malarial drugs such as chloroquine or amodiaquine have triggered great demand for artemisinin therapy which the WHO has recommended since 2001 in combination with other drugs as a malaria cure.

Counterfeit and sub-standard malaria drugs have become a problem in parts of Africa and Asia and the agency said fake malaria drugs had worsened drug resistance to the disease.

Malaria infects between 300 million and 500 million people each year, killing over 1 million of them, according to WHO. About 90 percent of malaria deaths occur in sub-Saharan Africa, with most victims children under the age of five.

Source-Bio-Bio Tech
'"/>




Page: 1 2

Related medicine news :

1. Epilepsy Needs To Be Managed Carefully
2. Carefully Monitored Treatment Can Help Those Who Suffer from Depression
3. Viral Haemorrhagic Septicaemia Attack On Farmed Trout
Post Your Comments:
(Date:8/29/2008)...INGTON, Aug. 29 /PRNewswire-USNewswire/ -- The fol...nt, Campaign for Tobacco-Free Kids:, For the seco...s had to,withdraw sponsorship and promotion of a c...international criticism for engaging in cigarette,...hilip Morris International has been forced to with...
(Date:8/29/2008)... First Walkathon to Benefit Muscu...Iselin, NJ (PRWEB) August 29, 2008 -- Students, fa...rd-Brown Iselin] (SBI), in New Jersey, raised $11,...r walkathon, last week. Proceeds from the event a...org [Ryan,s Quest]. The all-volunteer event was a...
(Date:8/29/2008)...WOOD, Ill., Aug. 29 /PRNewswire-FirstCall/ -- Land...ard of Directors declared a regular,quarterly cash...r of fiscal,2008. The dividend will be paid on Oct...er 12, 2008., About Landauer, Landauer is the le...,occupational and environmental radiation exposure...
(Date:8/29/2008)...oston Scientific obligation reduced from $250 to $...rstCall/ -- Boston Scientific,Corporation (NYSE: ... of,Marshall, Texas found two patents of Medtronic... conduct during the prosecution of the patents,bef..., A jury had previously found that certain Boston...
Breaking Medicine News(10 mins):Health News:Philip Morris International Forced to Drop Another Concert Sponsorship; Philippines Health Department Applauded for Taking Action 2Health News:Sanford-Brown Institute - Iselin Raises $11,000 for Ryan's Quest 2Health News:Court Rejects Two Medtronic Patents 2Health News:Court Rejects Two Medtronic Patents 3
...ksburg: Procter & Gamble and the Industrial Design...mpetitive grant of $40,000 to a Virginia Tech team...ollege of Architecture and Urban Affairs for the d... that can add more value to the lives of elderly p...
...uala Lumpur, Malaysia a two-year-old boy dies at t...symptoms of the hand, foot and mouth disease (HFMD...laysia. Totally the disease has killed about eight...he boy. The child hailing from the town of Kapit...
...ersity of Cincinnati (UC) researchers revealed tha...ual characteristics have higher risk for depressiv...f data through surveys which said that the risk fo...eater among respondents who reported negative reli...
...e Minister Manmohan Singh set up a task force to f...of doctors, nurses and lab technicians. The recrui...an opportunity to the unemployed. The move is bas...port submitted by National Commission on Macroecon...
Other Medicine News:
(Date:8/27/2008)...prednisone arm demonstrated a, significant surviv...se -, CAMBRIDGE, Mass., Aug. 27 /- M...nced the publication of results from the 682,patie...eek,s edition of the,New England Journal of Medici...fit and a 30 percent complete remission (CR) rate ...
(Date:8/27/2008)...al, expected by mid-2009 - - Data from second Pha...CKVILLE, Md., Aug. 27 /- Hu...nnounced it has completed enrollment,and initial d... 3,randomized clinical trials of LymphoStat-B(R) (...erythematosus (SLE). Belimumab is being developed ...
(Date:8/26/2008)...mafore Pharmaceuticals Inc.,presented data at the ...es,in Cancer in Washington, D.C., announcing the d... that demonstrate significant anticancer,activity ...molecular scaffold has been developed using,comput...3 kinase inhibitors,as well as isoform-selective s...
(Date:8/26/2008)...FirstCall/ -- XTENT, Inc.,(Nasdaq: XTNT ) today a...,from the CUSTOM II trial was published in the mos...ntervention. The lead author of the article was,Dr...nter Utrecht, Utrecht,The Netherlands on behalf o...es across Europe., The one-year CUSTOM II trial, ...
Breaking Medicine Technology:New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 2New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 3New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 4New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 5New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 6Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 2Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 3Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 4Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 5Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 6Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 2Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 3XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 2XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 3XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 4Older Americans are more socially engaged than many people may think 16988 1Older Americans are more socially engaged than many people may think 16988 2Older Americans are more socially engaged than many people may think 16988 3Is there anybody out there 3F 2916 1Is there anybody out there 3F 2916 255 Year Old Grandmother to Document Journey of Running Seven Marathons on Seven Continents on Run7on7 com 16984 155 Year Old Grandmother to Document Journey of Running Seven Marathons on Seven Continents on Run7on7 com 16984 255 Year Old Grandmother to Document Journey of Running Seven Marathons on Seven Continents on Run7on7 com 16984 3MEDEX Global Group Hires Industry Veteran Mike Roban as Vice President of Sales 16980 1MEDEX Global Group Hires Industry Veteran Mike Roban as Vice President of Sales 16980 2
...of Peregrine,s,Unique Selective Anti-VEGF Antibodi...l Cancer Models, TUSTIN, Calif., April 20, 2007 /P... Inc. , a clinical stage,biopharmaceutical company... treatment of cancer and hepatitis C virus infecti... presented at the recent,Centennial Annual Meeting...
...Rx Corporation,(NASDAQ:CYTR) today announced that ...clusively licensed to its majority-owned,subsidiar...,published in the April 2007 issue of peer-reviewe...hnology was developed by RXi,Co-founder, Scientifi...setts Medical School (UMMS) Professor of Biochemis...
Other Medicine Technology:Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 2Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 3Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 4Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 5Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 6Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 7CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 2CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 3CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 4
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
Medicine Products: